Notably, serum levels of BAFF were found to correlate with sarcoidosis disease activity, and the anti-CD20 monoclonal antibody rituximab has shown some clinical efficacy in patients with refractory sarcoidosis (60, 61). This evidence concerns the gene MS4A1 and sarcoidosis.